Early detection AESKU.GROUP specializes in innovative in vitro diagnostic products for early detection, diagnosis and prognosis of autoimmune and infectious diseases, allergies and food intolerances, presenting opportunities to cross-sell comprehensive diagnostic panels and complement existing lab workflows.

SARS-CoV-2 capability Recent launch of quantitative SARS-CoV-2 antibody tests indicates readiness to support pandemic-related testing programs, enabling sales discussions around serology solutions for surveillance, immunity assessment, and post-vaccination monitoring.

QC and portal expansion Introduction of AESQC IFA QC product line and AESQC.com web portal demonstrates commitment to quality control and digital resources, offering upsell potential for QA tools, training services, and enhanced compliance offerings to diagnostic labs.

Mid-market focus With 51-200 employees and revenue in the lower mid-market range, AESKU.GROUP sits between niche specialist suppliers and large incumbents, presenting a growth path through targeted lab partnerships, regional distributors, and joint development opportunities.

Tech-enabled research Utilizing modern tech stack (OpenCV, Google Analytics, WordPress) alongside an interdisciplinary network signals scalability and data-driven marketing/sales potential; leverage digital channels to build awareness, demos, and lead generation for new diagnostic solutions.